Hereditary Angioedema
Conditions
Keywords
HAE, Angioedema
Brief summary
This is a first-in-human, single-center, randomized, double-blind, placebo-controlled, single ascending dose study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single subcutaneous (SC) or intravenous (IV) administration of STAR-0215 in healthy adult participants.
Interventions
DRUGSTAR-0215 (SC)
STAR-0215 will be administered as an SC bolus injection.
DRUGPlacebo (SC)
Placebo will be administered as an SC bolus injection.
DRUGSTAR-0215 (IV)
STAR-0215 will be administered as an IV bolus injection.
DRUGPlacebo (IV)
Placebo will be administered as an IV bolus injection.
Sponsors
Astria Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Good health as determined by the Investigator based upon a medical evaluation, including medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory measurements. Assessments may be repeated per Investigator discretion. * Body mass index of 18 to 35 kilograms (kg)/square meter with a weight of at least 60 kg for men and at least 50 kg for women, with a maximum weight of 130 kg for any participant. * Female participants capable of becoming pregnant must have a negative serum pregnancy test at Screening, not be nursing, and must agree to use an effective method of contraception and abstain from egg donation or fertility treatment. * Male participants must agree to use an effective method of contraception and abstain from sperm donation.
Exclusion criteria
* Prior or ongoing medical condition (for example, gastrointestinal, renal, hepatic, dermatological, neurological or psychiatric, cardiovascular, respiratory, or hematological), medical history, physical examination, vital signs, ECG, or clinical laboratory abnormality that, in the Investigator's opinion, could adversely affect the safety of the participant. Assessments may be repeated once prior to dosing as needed per Investigator discretion. * Known sensitivity to the ingredients in STAR-0215. * Regular use of prescription or non-prescription drugs unless Investigator believes the medication(s) will not interfere with the study or compromise participant safety. * Participation in a recent clinical study involving receipt of an investigational product within 30 days prior to the first dose of study drug or exposure to more than 4 investigational products within 12 months prior to the first dose of study drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants Experiencing Treatment-emergent Adverse Events | Day 1 through Day 224 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum Concentration of STAR-0215 | Day 1 (pre-dose, up to 2 hours before study drug administration, and 2, 6, 12, 24, 48, 72, 96, and 120 hours post-dose); Days 14, 28, 56, 84, 112, 140, 168, 196, and 224 | Blood samples will be collected to measure the serum concentration of STAR-0215 before and after study drug administration. |
| Plasma Levels of Cleaved High-molecular-weight Kininogen | Day 1 (pre-dose, up to 2 hours before study drug administration, and 2, 6, 12, 24, 48, 72, 96, and 120 hours post-dose); Days 14, 28, 56, 84, 112, 140, 168, 196, and 224 | Blood samples will be collected to measure the plasma levels of cleaved high-molecular-weight kininogen (a measure of plasma kallikrein activity). |
| Number of Participants with Anti-drug Antibodies to STAR-0215 | Day 1 (pre-dose, up to 2 hours before study drug administration); Days 28, 56, 84, 112, 140, 168, 196, and 224 | Blood samples will be collected to assess the formation of STAR-0215 anti-drug antibodies in serum before and after study drug administration. |
Countries
United States
Outcome results
None listed